Release time：2023-10-12
On the morning of December 1, 2021, Jiangsu Industrial Technology Research Institute and Changzhou Science and Education City organized an expert group to carry out the second milestone acceptance of Changzhou Trending Medical Technology Co., Ltd.'s major project "LAMP-IDE rapid gene screening technology application".
The acceptance meeting was held in the company's conference room, Zhang Lei, assistant director of the biology and medicine department of Jiangsu Institute of Industry and Research, Luo Hong, senior business manager of the investment and finance department, Fan Junjun, member of the Party Working Committee of Changzhou Science and Education City and director of Changzhou National University Science and Technology Park Management Center, Liu Hong, professor and doctoral supervisor of the School of Biological Science and Medical Engineering of Southeast University, Wang Wenzhong, chairman of Kang Gene Technology Co., Ltd., Xu Jiafa, registered director of Jiangsu Shuoshi Gene Biotechnology Co., Ltd., and Guan Guoliang, chairman of the company, General Manager Chen Qiaoling attended the acceptance meeting. The simultaneous financial acceptance work is responsible for Pan Kun, deputy director of the investment and finance department of Jiangsu Industry and Research Institute.
The project accepted this time is "LAMP-IDE rapid genetic screening technology application", which aims at the current clinical application pain points of traditional genetic testing that cannot be detected on the spot, and develops a rapid genetic detection platform technology based on LAMP-IDE, which can achieve rapid detection anytime, anywhere, and the detection cost is low, easy to carry, and has a wide range of application scenarios.
Chairman Patrick kwan, as the project leader, reported to the acceptance experts from the aspects of project background, research content and indicators, project industrialization implementation, completion of R&D indicators, and use of funds, and answered the questions of the expert group in detail.
On the basis of fully listening to the report of Chairman Patrick kwan, the acceptance experts commented on the innovation of the project, the completion of project indicators, the progress of industrialization, and the planning of the next stage, and put forward many suggestions and guiding opinions. After expert discussion, the data provided by the "LAMP-IDE Rapid Gene Screening Technology Application" project met the acceptance requirements, and the R&D progress met the expected indicators, and it was unanimously agreed to pass the acceptance.
The successful holding of this milestone acceptance meeting marks that the second phase of the project of Changzhou Xianqian Medical Technology Co., Ltd. has been successfully completed, marking another important step towards the marketization of the company's products.
